product summary
request information :
company name :
LifeSpan Biosciences
product type :
antibody
product name :
Anti-RPL31
catalog :
LS-C158890
quantity :
price :
clonality :
polyclonal
host :
rabbit
reactivity :
human
application :
western blot, ELISA
more info or order :
product information
AntibodyID :
166210
AntibodyName :
LS-C158890
TargetSpecies :
Human
Host Species :
Rabbit
Product Name :
Anti-RPL31
Specificity :
Human RPL31
ClonalityDesc :
Polyclonal
AntigenModification :
aa60-87
PresentationDesc :
PBS, 0.09% sodium azide
ImmunogenType :
Synthetic peptide
ImmunogenDesc :
KLH-conjugated synthetic peptide from internal region of human RPL31.
PurificationDesc :
Immunoaffinity Chromatography
RecommendedStorageDesc :
Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.
Gene :
RPL31
StandardGeneSymbol :
RPL31
Reactivity :
Human
Usage :
WB (1:100 - 1:500)
Synonyms :
RPL31, 60S ribosomal protein L31, MMRPS32, L31, Ribosomal protein L31
SwissProtProtoID :
P62899
more info or order :
company information

LifeSpan Biosciences
2401 Fourth Avenue, Suite 900
Seattle, WA 98121
Seattle, WA 98121
antibodies@lsbio.com
www.lsbio.com1-206-464-1554
headquarters: usa
Since 1995, LifeSpan has been the industry leader in molecular pathology, specializing in the localization of proteins in normal and diseased tissues, both human and non-human. We offer more than 74,000 antibodies, custom designed immunohistochemistry (IHC) studies, immediately available human tissue IHC profiles for more than 500 proteins, and histology and pathology services. Our bank of 2 million specimens is available to support our customers' contract research studies and contains frozen and formalin-fixed (FFPE) normal and diseased tissues. Our contract services are comprehensive; they include study design, antibody sourcing and characterization, tissue sourcing and validation, immunolabeling, trouble shooting, and interpretation of the results by a LifeSpan pathologist.
related products
browse more products
questions and comments
